Soligenix Anti-Tumor Therapy Demonstrates Positive Efficacy

Armed with supportive data from Phase II and III trials, share price showing strength and Company to pursue partnership opportunities for novel molecule

Soligenix, Inc. (Nasdaq: SNGX) has demonstrated positive efficacy of dusquetide as an anti-tumor therapy in non-clinical animal studies. Previously published studies have also confirmed dusquetide’s efficacy in treating:

  • Breast cancer: As a stand-alone and combination anti-tumor therapy with radiation, chemotherapy and targeted therapy (MCF-7 breast cancer cell line)
  • Severe Oral Mucositis (SOM): Reduces the duration of SOM with the potential ancillary benefit of an acceleration in the clearance of tumor response and an increase in overall survival in patients receiving chemo-radiation for head and neck cancer.
  • And may have applications in treating other indications including multiple myeloma, liver cancer, lung cancer, intestinal cancer, colorectal cancer and ovarian cancer.

Dusquetide is a novel synthetic peptide that modulates the body’s innate immune system, including the response to tumors and the response of the tumors themselves. A review of the potential action of dusquetide is available here. Soligenix will pursue potential product and partnership opportunities for this novel molecule.

SNGX share price reacted favorably to this news, with a price increase of over 5% on the day, with nearly 10 times average volume.

Share this article:

Disclaimer

This communication was produced by Investors Prism, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Share this article:
Read Full Disclaimer

About the Author

Soligenix Anti-Tumor Therapy Demonstrates Positive Efficacy

Editor Investors Prism